Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Woodworth

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Annals of Neurology|March 13, 2010
Reply: To PMID 19798640James Woodworth, Meena Subramanyam, Mark Rogge
Dermatology Online Journal|April 28, 2006
Results of a randomized open-label crossover study of the bioequivalence of subcutaneous versus intramuscular administration of alefaceptMarianne T Sweetser, James Woodworth, Suzanne Swan, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|May 22, 2023
Metabolism, pharmacokinetics and excretion of [<sup>14</sup>C]dimethyl fumarate in healthy volunteers: an example of xenobiotic biotransformation following endogenous metabolic pathwaysLin Xu, Chi-Chi Peng, Kate Dawson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007
Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemiaJohn C Byrd, Susan O'Brien, Ian W Flinn, et al.
Blood|October 22, 2009
Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemiaJohn C Byrd, Thomas J Kipps, Ian W Flinn, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Annals of Neurology|March 13, 2010
Reply: To PMID 19798640James Woodworth, Meena Subramanyam, Mark Rogge
Dermatology Online Journal|April 28, 2006
Results of a randomized open-label crossover study of the bioequivalence of subcutaneous versus intramuscular administration of alefaceptMarianne T Sweetser, James Woodworth, Suzanne Swan, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|May 22, 2023
Metabolism, pharmacokinetics and excretion of [<sup>14</sup>C]dimethyl fumarate in healthy volunteers: an example of xenobiotic biotransformation following endogenous metabolic pathwaysLin Xu, Chi-Chi Peng, Kate Dawson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007
Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemiaJohn C Byrd, Susan O'Brien, Ian W Flinn, et al.
Blood|October 22, 2009
Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemiaJohn C Byrd, Thomas J Kipps, Ian W Flinn, et al.
Pageof 1